KRAS and cancer: Unfortunately, we found that only approximately one-third of patients with advanced hotspot KRAS+/TP53+ mutant cancers received treatment in a phase I clinical trial, much less than the overall rate of 55% of all patients who were referred to phase I clinical trials at the same institution [25].